D. J. Deangelo - Concepedia

Author

D. J. Deangelo

Also Known As

D. Deangelo, D. J. Deangelo, D.J. DeAngelo, Dan DeAngelo, Dan Deangelo

Publications

342

Citations

H-Index

Concepts

All Affiliations

D. J. Deangelo is an author at Dana-Farber Cancer Institute specializing in health sciences, medicine, and oncology.

#	Concept	H-Index	Publications	Citations
1	Health Sciences	3	3	271
2	Medicine	3	3	271
3	Immunology	2	2	240
4	Critical Care Medicine	1	1	31
5	Medical Laboratory Science	1	1	31

D. J. Deangelo

Publications

317

Citations

H-Index

Page 1

	Year	Citations
A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias D. J. Deangelo, Richard M. Stone, L. B. Silverman, Journal of Clinical Oncology Gamma SecretaseImmunologyPharmacotherapyImmunotherapyTumor Biology	2006	226
Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction Catia Fonseca, Robert J. Soiffer, Vincent T. Ho, Blood	2008	36
Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies Eric K. Rowinsky, Johann S. de Bono, D. J. Deangelo, Journal of Clinical Oncology Cardiovascular PharmacologyPathologyPharmacotherapyOutlier EcgsCardiac Monitoring	2005	31
A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies Oliver G. Ottmann, D. J. Deangelo, R. M. Stone, Journal of Clinical Oncology ImmunologyPharmacotherapyHdac ActivityMyeloid NeoplasiaHematological Malignancy	2004	14
S830 AVAPRITINIB, A POTENT AND SELECTIVE INHIBITOR OF KIT D816V, INDUCES COMPLETE AND DURABLE RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM) Deepti Radia, M. Deininger, Jason Gotlib, HemaSphere	2019	10

Page 1